BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 37254219)

  • 1. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
    Wei S; Xing J; Lu K; Wang K; Yu W
    Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NPM3 as an Unfavorable Prognostic Biomarker Involved in Oncogenic Pathways of Lung Adenocarcinoma
    Chen L; Yang D; Huang F; Xu W; Luo X; Mei L; He Y
    Comb Chem High Throughput Screen; 2024; 27(2):203-213. PubMed ID: 37114782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma.
    Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L
    BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma.
    Shi J; Lv X; Li W; Ming Z; Zeng L; Yuan J; Chen Y; Liu B; Yang S
    Thorac Cancer; 2021 Sep; 12(17):2324-2338. PubMed ID: 34297484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis of the prognostic and immunological role of nucleophosmin/nucleoplasmin 3 (
    Wei Q; Zhou J; Wang X; Li Z; Chen X; Chen K; Jiang R
    Cancer Pathog Ther; 2023 Oct; 1(4):238-252. PubMed ID: 38327603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Expression of RTN1 in Lung Adenocarcinoma and 
Its Effect on Immune Microenvironment].
    Zhu S; Zu L; Xu S
    Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma.
    Hu A; Tang K; Liu J; Han X; Chen Q
    Medicine (Baltimore); 2023 May; 102(21):e33755. PubMed ID: 37233443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma.
    Hou Y; Xiang B; Yang Z; Liu J; Xu D; Geng L; Zhan M; Xu Y; Zhang B
    Int J Immunopathol Pharmacol; 2023; 37():3946320231202748. PubMed ID: 37731383
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.
    Jiang W; Wei Q; Xie H; Wu D; He H; Lv X
    Anal Cell Pathol (Amst); 2023; 2023():4522045. PubMed ID: 37416927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.
    Chen M; Zhang S; Wang F; He J; Jiang W; Zhang L
    J Transl Med; 2024 Feb; 22(1):209. PubMed ID: 38414025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulated CDH3 is correlated with a better prognosis for LUAD and decreases proliferation and migration of lung cancer cells.
    Ma W; Hu J
    Genes Genomics; 2024 Jun; 46(6):713-731. PubMed ID: 38064156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic expression analysis of the CELSR family reveals the importance of CELSR3 in human lung adenocarcinoma.
    Li Y; Zhu L; Hao R; Li Y; Zhao Q; Li S
    J Cell Mol Med; 2021 May; 25(9):4349-4362. PubMed ID: 33811453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
    Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.